We are live on ! Find out more
LOXO

Loxo Oncology, Inc
LOXO

Delisted

LOXO was delisted on the 14th of February, 2019.

Back to rankings

1 hedge funds and large institutions have $65K invested in Loxo Oncology, Inc in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 231 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 232 → 1 (-231)

100% less funds holding in top 10

Funds holding in top 10: 7 → 0 (-7)

100% less capital invested

Capital invested by funds: $4.15B → $65K (-$4.15B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 231

Holders
1
Holders Change
-231
Holders Change %
-99.57%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
231
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$391M
2
BlackRock
BlackRock
New York
-$319M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$296M
4
AC
Aisling Capital
New York
-$286M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$280M
Name Holding Trade Value Shares
Change 		Change in
Stake
IUHSA
1
Itau Unibanco Holding S.A.
Brazil
$65K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
– -$391M -2,789,978 Closed
BlackRock
3
BlackRock
New York
– -$319M -2,280,968 Closed
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
– -$296M -2,116,328 Closed
AC
5
Aisling Capital
New York
– -$286M -2,038,920 Closed
Fidelity Investments
6
Fidelity Investments
Massachusetts
– -$280M -1,997,330 Closed
Wellington Management Group
7
Wellington Management Group
Massachusetts
– -$251M -1,793,587 Closed
Sands Capital Management
8
Sands Capital Management
Virginia
– -$241M -1,722,467 Closed
O
9
OppenheimerFunds
New York
– -$142M -1,014,058 Closed
Point72 Asset Management
10
Point72 Asset Management
Connecticut
– -$139M -990,719 Closed
State Street
11
State Street
Massachusetts
– -$125M -894,207 Closed
Fidelity International
12
Fidelity International
Bermuda
– -$77.6M -554,177 Closed
AllianceBernstein
13
AllianceBernstein
Tennessee
– -$71.3M -508,691 Closed
Norges Bank
14
Norges Bank
Norway
– -$60.8M -434,018 Closed
EAM
15
Eagle Asset Management
Florida
– -$52M -371,061 Closed
CC
16
Casdin Capital
New York
– -$50.4M -360,000 Closed
PC
17
Polar Capital
United Kingdom
– -$50M -356,621 Closed
Northern Trust
18
Northern Trust
Illinois
– -$49.5M -353,731 Closed
Geode Capital Management
19
Geode Capital Management
Massachusetts
– -$46.3M -330,898 Closed
ACA
20
Avoro Capital Advisors
New York
– -$45.5M -325,000 Closed
TCM
21
TimesSquare Capital Management
New York
– -$42.8M -305,869 Closed
Ameriprise
22
Ameriprise
Minnesota
– -$42.6M -304,086 Closed
Victory Capital Management
23
Victory Capital Management
Texas
– -$39.8M -284,332 Closed
EAM
24
Eventide Asset Management
Massachusetts
– -$38.4M -274,000 Closed
CTA
25
Carillon Tower Advisers
Florida
– -$35.9M -256,146 Closed
1
2 3 4 5

LOXO Hedge Fund Activity: Q1 2019 in Review

1 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Loxo Oncology, Inc (LOXO) for Q1 2019, worth a combined $65K — down 100% from $4.15B a quarter earlier.

Sellers outnumbered buyers: 231 funds closed out of LOXO and 0 opened new positions — a net loss of 231 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $391M sold.

  • 1 institutional investor held Loxo Oncology, Inc (LOXO) as of Q1 2019, down from 232 in Q4 2018.
  • Funds reported $65K of Loxo Oncology, Inc stock for Q1 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Loxo Oncology, Inc positions in Q1 2019 and 231 closed out, a net change of -231 holders.
  • The largest Loxo Oncology, Inc seller in Q1 2019 was Vanguard Group, an estimated $391M sold.

Based on aggregated 13F filings for Q1 2019.